Pharmacokinetics of Recombinant Interleukin 2 in Humans

Michael W. Konrad, George Hemstreet, Evan M. Hersh, Peter W.A. Mansell, Roland Mertelsmann, Jonathan E. Kolitz, Edward C. Bradley

Research output: Contribution to journalArticlepeer-review

211 Scopus citations


This report summarizes the pharmacokinetics in humans of recombinant interleukin 2 (IL-2) given as an i.v. bolus, i.v. or i.p. infusion, and i.m. or s.c. injection. Immediately after an i.v. bolus the serum IL-2 level equals the dose divided by the plasma volume, in a typical human 650 units/ml for a dose of 104 units/m2. The level initially decreases with a half-life of 12.9 min, followed by a slower phase with a half-life of 85 min out to 4 h after the bolus. The median steady state level during an i.v. infusion of 104 units/m2 over 6 h is 41 units/ml. A clearance rate of approximately 120 ml/min is obtained from either the i.v. bolus or infusion data and is consistent with the renal filtration being the major route of clearance. Serum levels remain fairly constant for about 8 h after s.c. or i.m. injection but are approximately 2% of the level seen immediately after an i.v. bolus. The area under the time-concentration curve suggests that about 30% of the IL-2 activity is transported from the site of an i.m. injection to the blood. After i.p. infusion IL-2 is only slowly transported to the blood. The median serum IL-2 levels are 430-fold lower than levels in the i.p. fluid and decrease with a median half-life of 63 h.

Original languageEnglish (US)
Pages (from-to)2009-2017
Number of pages9
JournalCancer Research
Issue number7
StatePublished - Apr 15 1990
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Pharmacokinetics of Recombinant Interleukin 2 in Humans'. Together they form a unique fingerprint.

Cite this